nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—ovarian cancer—polycystic ovary syndrome	0.301	1	CtDrD
Doxorubicin—AKR1C3—polycystic ovary syndrome	0.145	0.656	CbGaD
Doxorubicin—NDUFS7—Metformin—polycystic ovary syndrome	0.117	0.333	CbGbCtD
Doxorubicin—NDUFS2—Metformin—polycystic ovary syndrome	0.117	0.333	CbGbCtD
Doxorubicin—NDUFS3—Metformin—polycystic ovary syndrome	0.117	0.333	CbGbCtD
Doxorubicin—TOP2A—polycystic ovary syndrome	0.0761	0.344	CbGaD
Doxorubicin—NOS3—tunica intima—polycystic ovary syndrome	0.00223	0.0502	CbGeAlD
Doxorubicin—Valrubicin—TOP2A—polycystic ovary syndrome	0.000845	0.403	CrCbGaD
Doxorubicin—Tooth abscess—Metformin—polycystic ovary syndrome	0.000821	0.0505	CcSEcCtD
Doxorubicin—CBR3—embryo—polycystic ovary syndrome	0.000797	0.0179	CbGeAlD
Doxorubicin—NOS2—adrenal gland—polycystic ovary syndrome	0.00076	0.0171	CbGeAlD
Doxorubicin—Hypothermia—Metformin—polycystic ovary syndrome	0.000612	0.0376	CcSEcCtD
Doxorubicin—Body temperature decreased—Metformin—polycystic ovary syndrome	0.000612	0.0376	CcSEcCtD
Doxorubicin—CBR3—endometrium—polycystic ovary syndrome	0.000583	0.0131	CbGeAlD
Doxorubicin—ABCB8—pituitary gland—polycystic ovary syndrome	0.000548	0.0123	CbGeAlD
Doxorubicin—SLC22A16—endocrine gland—polycystic ovary syndrome	0.000546	0.0123	CbGeAlD
Doxorubicin—ABCB8—adipose tissue—polycystic ovary syndrome	0.000546	0.0123	CbGeAlD
Doxorubicin—Nail disorder—Metformin—polycystic ovary syndrome	0.000529	0.0325	CcSEcCtD
Doxorubicin—CBR3—adipose tissue—polycystic ovary syndrome	0.000526	0.0118	CbGeAlD
Doxorubicin—AKR1A1—adrenal cortex—polycystic ovary syndrome	0.000504	0.0113	CbGeAlD
Doxorubicin—ABCB8—adrenal gland—polycystic ovary syndrome	0.00049	0.011	CbGeAlD
Doxorubicin—Idarubicin—TOP2A—polycystic ovary syndrome	0.000486	0.231	CrCbGaD
Doxorubicin—CBR3—adrenal gland—polycystic ovary syndrome	0.000471	0.0106	CbGeAlD
Doxorubicin—ABCB8—female gonad—polycystic ovary syndrome	0.000457	0.0103	CbGeAlD
Doxorubicin—AKR1A1—endometrium—polycystic ovary syndrome	0.00045	0.0101	CbGeAlD
Doxorubicin—Fungal infection—Metformin—polycystic ovary syndrome	0.000444	0.0273	CcSEcCtD
Doxorubicin—CBR3—female gonad—polycystic ovary syndrome	0.00044	0.00989	CbGeAlD
Doxorubicin—CBR3—vagina—polycystic ovary syndrome	0.000437	0.00983	CbGeAlD
Doxorubicin—ABCB8—endocrine gland—polycystic ovary syndrome	0.000425	0.00956	CbGeAlD
Doxorubicin—Rigors—Metformin—polycystic ovary syndrome	0.00042	0.0259	CcSEcCtD
Doxorubicin—AKR1A1—uterus—polycystic ovary syndrome	0.000415	0.00934	CbGeAlD
Doxorubicin—Blood disorder—Metformin—polycystic ovary syndrome	0.000411	0.0253	CcSEcCtD
Doxorubicin—AKR1A1—pituitary gland—polycystic ovary syndrome	0.000407	0.00917	CbGeAlD
Doxorubicin—AKR1A1—adipose tissue—polycystic ovary syndrome	0.000406	0.00913	CbGeAlD
Doxorubicin—AURKA—endometrium—polycystic ovary syndrome	0.00038	0.00856	CbGeAlD
Doxorubicin—NDUFS2—adrenal cortex—polycystic ovary syndrome	0.00038	0.00855	CbGeAlD
Doxorubicin—NDUFS3—adrenal cortex—polycystic ovary syndrome	0.000375	0.00844	CbGeAlD
Doxorubicin—NDUFS7—adipose tissue—polycystic ovary syndrome	0.000369	0.0083	CbGeAlD
Doxorubicin—Epirubicin—TOP2A—polycystic ovary syndrome	0.000368	0.175	CrCbGaD
Doxorubicin—AKR1A1—adrenal gland—polycystic ovary syndrome	0.000364	0.00819	CbGeAlD
Doxorubicin—DHCR7—adrenal cortex—polycystic ovary syndrome	0.000356	0.00802	CbGeAlD
Doxorubicin—AURKA—uterus—polycystic ovary syndrome	0.000351	0.00789	CbGeAlD
Doxorubicin—AURKA—pituitary gland—polycystic ovary syndrome	0.000344	0.00775	CbGeAlD
Doxorubicin—AKR1A1—female gonad—polycystic ovary syndrome	0.000339	0.00764	CbGeAlD
Doxorubicin—NDUFS2—endometrium—polycystic ovary syndrome	0.000339	0.00763	CbGeAlD
Doxorubicin—AKR1A1—vagina—polycystic ovary syndrome	0.000337	0.00759	CbGeAlD
Doxorubicin—NDUFS3—endometrium—polycystic ovary syndrome	0.000335	0.00754	CbGeAlD
Doxorubicin—NDUFS7—adrenal gland—polycystic ovary syndrome	0.000331	0.00745	CbGeAlD
Doxorubicin—YWHAG—adrenal cortex—polycystic ovary syndrome	0.000327	0.00736	CbGeAlD
Doxorubicin—Neuropathy—Metformin—polycystic ovary syndrome	0.000322	0.0198	CcSEcCtD
Doxorubicin—AKR1A1—endocrine gland—polycystic ovary syndrome	0.000316	0.0071	CbGeAlD
Doxorubicin—NDUFS2—uterus—polycystic ovary syndrome	0.000312	0.00703	CbGeAlD
Doxorubicin—NDUFS3—uterus—polycystic ovary syndrome	0.000309	0.00695	CbGeAlD
Doxorubicin—NDUFS7—female gonad—polycystic ovary syndrome	0.000308	0.00694	CbGeAlD
Doxorubicin—AURKA—adrenal gland—polycystic ovary syndrome	0.000308	0.00692	CbGeAlD
Doxorubicin—NDUFS2—pituitary gland—polycystic ovary syndrome	0.000307	0.00691	CbGeAlD
Doxorubicin—NDUFS7—vagina—polycystic ovary syndrome	0.000307	0.0069	CbGeAlD
Doxorubicin—NDUFS2—adipose tissue—polycystic ovary syndrome	0.000306	0.00688	CbGeAlD
Doxorubicin—CYP3A4—urine—polycystic ovary syndrome	0.000304	0.00684	CbGeAlD
Doxorubicin—NDUFS3—pituitary gland—polycystic ovary syndrome	0.000303	0.00682	CbGeAlD
Doxorubicin—NDUFS3—adipose tissue—polycystic ovary syndrome	0.000302	0.00679	CbGeAlD
Doxorubicin—CYP2D6—urine—polycystic ovary syndrome	0.000299	0.00673	CbGeAlD
Doxorubicin—RALBP1—adrenal cortex—polycystic ovary syndrome	0.000295	0.00665	CbGeAlD
Doxorubicin—YWHAG—endometrium—polycystic ovary syndrome	0.000292	0.00657	CbGeAlD
Doxorubicin—DHCR7—pituitary gland—polycystic ovary syndrome	0.000288	0.00648	CbGeAlD
Doxorubicin—NDUFS7—endocrine gland—polycystic ovary syndrome	0.000287	0.00646	CbGeAlD
Doxorubicin—DHCR7—adipose tissue—polycystic ovary syndrome	0.000287	0.00646	CbGeAlD
Doxorubicin—AURKA—female gonad—polycystic ovary syndrome	0.000287	0.00645	CbGeAlD
Doxorubicin—AURKA—vagina—polycystic ovary syndrome	0.000285	0.00642	CbGeAlD
Doxorubicin—XDH—endometrium—polycystic ovary syndrome	0.000285	0.00641	CbGeAlD
Doxorubicin—ABCC6—adipose tissue—polycystic ovary syndrome	0.00028	0.00629	CbGeAlD
Doxorubicin—CBR1—adrenal cortex—polycystic ovary syndrome	0.000276	0.00621	CbGeAlD
Doxorubicin—NDUFS2—adrenal gland—polycystic ovary syndrome	0.000274	0.00617	CbGeAlD
Doxorubicin—AKR1C3—adrenal cortex—polycystic ovary syndrome	0.000272	0.00613	CbGeAlD
Doxorubicin—NDUFS3—adrenal gland—polycystic ovary syndrome	0.000271	0.00609	CbGeAlD
Doxorubicin—YWHAG—uterus—polycystic ovary syndrome	0.000269	0.00606	CbGeAlD
Doxorubicin—AURKA—endocrine gland—polycystic ovary syndrome	0.000267	0.006	CbGeAlD
Doxorubicin—YWHAG—pituitary gland—polycystic ovary syndrome	0.000264	0.00595	CbGeAlD
Doxorubicin—RALBP1—endometrium—polycystic ovary syndrome	0.000264	0.00594	CbGeAlD
Doxorubicin—YWHAG—adipose tissue—polycystic ovary syndrome	0.000263	0.00592	CbGeAlD
Doxorubicin—Renal impairment—Metformin—polycystic ovary syndrome	0.000262	0.0161	CcSEcCtD
Doxorubicin—Daunorubicin—TOP2A—polycystic ovary syndrome	0.00026	0.124	CrCbGaD
Doxorubicin—DHCR7—adrenal gland—polycystic ovary syndrome	0.000257	0.00579	CbGeAlD
Doxorubicin—NDUFS2—female gonad—polycystic ovary syndrome	0.000256	0.00575	CbGeAlD
Doxorubicin—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.000255	0.0157	CcSEcCtD
Doxorubicin—Lethargy—Metformin—polycystic ovary syndrome	0.000254	0.0156	CcSEcCtD
Doxorubicin—NDUFS2—vagina—polycystic ovary syndrome	0.000254	0.00572	CbGeAlD
Doxorubicin—NDUFS3—female gonad—polycystic ovary syndrome	0.000252	0.00568	CbGeAlD
Doxorubicin—NDUFS3—vagina—polycystic ovary syndrome	0.000251	0.00565	CbGeAlD
Doxorubicin—Pain in extremity—Metformin—polycystic ovary syndrome	0.000249	0.0153	CcSEcCtD
Doxorubicin—POR—adrenal cortex—polycystic ovary syndrome	0.000249	0.0056	CbGeAlD
Doxorubicin—CBR1—endometrium—polycystic ovary syndrome	0.000246	0.00554	CbGeAlD
Doxorubicin—Migraine—Metformin—polycystic ovary syndrome	0.000245	0.0151	CcSEcCtD
Doxorubicin—AKR1C3—endometrium—polycystic ovary syndrome	0.000243	0.00547	CbGeAlD
Doxorubicin—RALBP1—uterus—polycystic ovary syndrome	0.000243	0.00547	CbGeAlD
Doxorubicin—DHCR7—female gonad—polycystic ovary syndrome	0.00024	0.0054	CbGeAlD
Doxorubicin—NOS1—endocrine gland—polycystic ovary syndrome	0.000239	0.00538	CbGeAlD
Doxorubicin—RALBP1—pituitary gland—polycystic ovary syndrome	0.000239	0.00537	CbGeAlD
Doxorubicin—DHCR7—vagina—polycystic ovary syndrome	0.000238	0.00537	CbGeAlD
Doxorubicin—NDUFS2—endocrine gland—polycystic ovary syndrome	0.000238	0.00535	CbGeAlD
Doxorubicin—RALBP1—adipose tissue—polycystic ovary syndrome	0.000238	0.00535	CbGeAlD
Doxorubicin—YWHAG—adrenal gland—polycystic ovary syndrome	0.000236	0.00531	CbGeAlD
Doxorubicin—NDUFS3—endocrine gland—polycystic ovary syndrome	0.000235	0.00529	CbGeAlD
Doxorubicin—Dehydration—Metformin—polycystic ovary syndrome	0.000232	0.0142	CcSEcCtD
Doxorubicin—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00023	0.0141	CcSEcCtD
Doxorubicin—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000227	0.014	CcSEcCtD
Doxorubicin—CBR1—uterus—polycystic ovary syndrome	0.000227	0.00511	CbGeAlD
Doxorubicin—Breast disorder—Metformin—polycystic ovary syndrome	0.000225	0.0138	CcSEcCtD
Doxorubicin—AKR1C3—uterus—polycystic ovary syndrome	0.000224	0.00504	CbGeAlD
Doxorubicin—DHCR7—endocrine gland—polycystic ovary syndrome	0.000223	0.00502	CbGeAlD
Doxorubicin—CBR1—pituitary gland—polycystic ovary syndrome	0.000223	0.00501	CbGeAlD
Doxorubicin—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000223	0.0137	CcSEcCtD
Doxorubicin—POR—endometrium—polycystic ovary syndrome	0.000222	0.005	CbGeAlD
Doxorubicin—CBR1—adipose tissue—polycystic ovary syndrome	0.000222	0.00499	CbGeAlD
Doxorubicin—NQO1—adrenal cortex—polycystic ovary syndrome	0.000221	0.00497	CbGeAlD
Doxorubicin—YWHAG—female gonad—polycystic ovary syndrome	0.00022	0.00495	CbGeAlD
Doxorubicin—AKR1C3—pituitary gland—polycystic ovary syndrome	0.00022	0.00495	CbGeAlD
Doxorubicin—AKR1C3—adipose tissue—polycystic ovary syndrome	0.000219	0.00493	CbGeAlD
Doxorubicin—YWHAG—vagina—polycystic ovary syndrome	0.000219	0.00492	CbGeAlD
Doxorubicin—ABCC6—endocrine gland—polycystic ovary syndrome	0.000217	0.00489	CbGeAlD
Doxorubicin—Abdominal distension—Metformin—polycystic ovary syndrome	0.000217	0.0133	CcSEcCtD
Doxorubicin—Influenza—Metformin—polycystic ovary syndrome	0.000215	0.0132	CcSEcCtD
Doxorubicin—XDH—vagina—polycystic ovary syndrome	0.000213	0.0048	CbGeAlD
Doxorubicin—RALBP1—adrenal gland—polycystic ovary syndrome	0.000213	0.0048	CbGeAlD
Doxorubicin—Pancreatitis—Metformin—polycystic ovary syndrome	0.000211	0.013	CcSEcCtD
Doxorubicin—NOS3—adrenal gland—polycystic ovary syndrome	0.00021	0.00472	CbGeAlD
Doxorubicin—Angina pectoris—Metformin—polycystic ovary syndrome	0.00021	0.0129	CcSEcCtD
Doxorubicin—TOP2A—endometrium—polycystic ovary syndrome	0.000207	0.00466	CbGeAlD
Doxorubicin—YWHAG—endocrine gland—polycystic ovary syndrome	0.000205	0.00461	CbGeAlD
Doxorubicin—Neutropenia—Metformin—polycystic ovary syndrome	0.000201	0.0124	CcSEcCtD
Doxorubicin—POR—pituitary gland—polycystic ovary syndrome	0.000201	0.00452	CbGeAlD
Doxorubicin—POR—adipose tissue—polycystic ovary syndrome	0.0002	0.0045	CbGeAlD
Doxorubicin—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.0002	0.0123	CcSEcCtD
Doxorubicin—XDH—endocrine gland—polycystic ovary syndrome	0.0002	0.00449	CbGeAlD
Doxorubicin—CBR1—adrenal gland—polycystic ovary syndrome	0.000199	0.00448	CbGeAlD
Doxorubicin—RALBP1—female gonad—polycystic ovary syndrome	0.000199	0.00447	CbGeAlD
Doxorubicin—ABCC3—adrenal cortex—polycystic ovary syndrome	0.000198	0.00446	CbGeAlD
Doxorubicin—RALBP1—vagina—polycystic ovary syndrome	0.000198	0.00445	CbGeAlD
Doxorubicin—ABCC10—adrenal cortex—polycystic ovary syndrome	0.000197	0.00444	CbGeAlD
Doxorubicin—NQO1—endometrium—polycystic ovary syndrome	0.000197	0.00444	CbGeAlD
Doxorubicin—AKR1C3—adrenal gland—polycystic ovary syndrome	0.000197	0.00442	CbGeAlD
Doxorubicin—ABCB11—endocrine gland—polycystic ovary syndrome	0.000195	0.00439	CbGeAlD
Doxorubicin—NOS3—vagina—polycystic ovary syndrome	0.000194	0.00437	CbGeAlD
Doxorubicin—Infestation NOS—Metformin—polycystic ovary syndrome	0.000192	0.0118	CcSEcCtD
Doxorubicin—Infestation—Metformin—polycystic ovary syndrome	0.000192	0.0118	CcSEcCtD
Doxorubicin—Drowsiness—Metformin—polycystic ovary syndrome	0.000192	0.0118	CcSEcCtD
Doxorubicin—TOP2A—uterus—polycystic ovary syndrome	0.000191	0.00429	CbGeAlD
Doxorubicin—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000188	0.0116	CcSEcCtD
Doxorubicin—TOP2A—adipose tissue—polycystic ovary syndrome	0.000187	0.0042	CbGeAlD
Doxorubicin—CBR1—female gonad—polycystic ovary syndrome	0.000186	0.00418	CbGeAlD
Doxorubicin—RALBP1—endocrine gland—polycystic ovary syndrome	0.000185	0.00416	CbGeAlD
Doxorubicin—CBR1—vagina—polycystic ovary syndrome	0.000184	0.00415	CbGeAlD
Doxorubicin—AKR1C3—female gonad—polycystic ovary syndrome	0.000183	0.00413	CbGeAlD
Doxorubicin—AKR1C3—vagina—polycystic ovary syndrome	0.000182	0.0041	CbGeAlD
Doxorubicin—NOS3—endocrine gland—polycystic ovary syndrome	0.000182	0.00409	CbGeAlD
Doxorubicin—NQO1—uterus—polycystic ovary syndrome	0.000182	0.00409	CbGeAlD
Doxorubicin—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000182	0.0112	CcSEcCtD
Doxorubicin—POR—adrenal gland—polycystic ovary syndrome	0.000179	0.00404	CbGeAlD
Doxorubicin—NQO1—pituitary gland—polycystic ovary syndrome	0.000179	0.00402	CbGeAlD
Doxorubicin—NQO1—adipose tissue—polycystic ovary syndrome	0.000178	0.004	CbGeAlD
Doxorubicin—ABCC10—endometrium—polycystic ovary syndrome	0.000176	0.00397	CbGeAlD
Doxorubicin—Bradycardia—Metformin—polycystic ovary syndrome	0.000175	0.0108	CcSEcCtD
Doxorubicin—Rhinitis—Metformin—polycystic ovary syndrome	0.000173	0.0106	CcSEcCtD
Doxorubicin—CBR1—endocrine gland—polycystic ovary syndrome	0.000173	0.00388	CbGeAlD
Doxorubicin—Hepatitis—Metformin—polycystic ovary syndrome	0.000172	0.0106	CcSEcCtD
Doxorubicin—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000171	0.0105	CcSEcCtD
Doxorubicin—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00017	0.0104	CcSEcCtD
Doxorubicin—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000169	0.0104	CcSEcCtD
Doxorubicin—POR—female gonad—polycystic ovary syndrome	0.000167	0.00377	CbGeAlD
Doxorubicin—TOP2A—adrenal gland—polycystic ovary syndrome	0.000167	0.00377	CbGeAlD
Doxorubicin—POR—vagina—polycystic ovary syndrome	0.000166	0.00374	CbGeAlD
Doxorubicin—ABCC10—uterus—polycystic ovary syndrome	0.000162	0.00365	CbGeAlD
Doxorubicin—Eye disorder—Metformin—polycystic ovary syndrome	0.000161	0.0099	CcSEcCtD
Doxorubicin—Flushing—Metformin—polycystic ovary syndrome	0.00016	0.00984	CcSEcCtD
Doxorubicin—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00016	0.00984	CcSEcCtD
Doxorubicin—ABCC3—adipose tissue—polycystic ovary syndrome	0.00016	0.00359	CbGeAlD
Doxorubicin—NQO1—adrenal gland—polycystic ovary syndrome	0.000159	0.00359	CbGeAlD
Doxorubicin—ABCC10—pituitary gland—polycystic ovary syndrome	0.000159	0.00359	CbGeAlD
Doxorubicin—ABCC10—adipose tissue—polycystic ovary syndrome	0.000159	0.00357	CbGeAlD
Doxorubicin—Angiopathy—Metformin—polycystic ovary syndrome	0.000156	0.00962	CcSEcCtD
Doxorubicin—TOP2A—female gonad—polycystic ovary syndrome	0.000156	0.00351	CbGeAlD
Doxorubicin—POR—endocrine gland—polycystic ovary syndrome	0.000156	0.0035	CbGeAlD
Doxorubicin—Immune system disorder—Metformin—polycystic ovary syndrome	0.000156	0.00957	CcSEcCtD
Doxorubicin—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000155	0.00955	CcSEcCtD
Doxorubicin—TOP2A—vagina—polycystic ovary syndrome	0.000155	0.00349	CbGeAlD
Doxorubicin—Chills—Metformin—polycystic ovary syndrome	0.000155	0.00951	CcSEcCtD
Doxorubicin—Erythema—Metformin—polycystic ovary syndrome	0.00015	0.00923	CcSEcCtD
Doxorubicin—Malnutrition—Metformin—polycystic ovary syndrome	0.00015	0.00923	CcSEcCtD
Doxorubicin—NQO1—female gonad—polycystic ovary syndrome	0.000149	0.00335	CbGeAlD
Doxorubicin—Flatulence—Metformin—polycystic ovary syndrome	0.000148	0.00909	CcSEcCtD
Doxorubicin—NQO1—vagina—polycystic ovary syndrome	0.000148	0.00333	CbGeAlD
Doxorubicin—Dysgeusia—Metformin—polycystic ovary syndrome	0.000147	0.00903	CcSEcCtD
Doxorubicin—Muscle spasms—Metformin—polycystic ovary syndrome	0.000144	0.00887	CcSEcCtD
Doxorubicin—ABCC3—adrenal gland—polycystic ovary syndrome	0.000143	0.00322	CbGeAlD
Doxorubicin—ABCC10—adrenal gland—polycystic ovary syndrome	0.000142	0.00321	CbGeAlD
Doxorubicin—Vision blurred—Metformin—polycystic ovary syndrome	0.000141	0.0087	CcSEcCtD
Doxorubicin—ABCC1—adrenal cortex—polycystic ovary syndrome	0.00014	0.00314	CbGeAlD
Doxorubicin—Daunorubicin—CYP1A1—polycystic ovary syndrome	0.000139	0.0664	CrCbGaD
Doxorubicin—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000139	0.00856	CcSEcCtD
Doxorubicin—NQO1—endocrine gland—polycystic ovary syndrome	0.000138	0.00311	CbGeAlD
Doxorubicin—Malaise—Metformin—polycystic ovary syndrome	0.000135	0.00832	CcSEcCtD
Doxorubicin—Syncope—Metformin—polycystic ovary syndrome	0.000135	0.00827	CcSEcCtD
Doxorubicin—ABCC3—female gonad—polycystic ovary syndrome	0.000133	0.003	CbGeAlD
Doxorubicin—ABCC10—female gonad—polycystic ovary syndrome	0.000133	0.00299	CbGeAlD
Doxorubicin—Palpitations—Metformin—polycystic ovary syndrome	0.000133	0.00815	CcSEcCtD
Doxorubicin—ABCC10—vagina—polycystic ovary syndrome	0.000132	0.00297	CbGeAlD
Doxorubicin—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000132	0.00811	CcSEcCtD
Doxorubicin—Hypertension—Metformin—polycystic ovary syndrome	0.00013	0.00797	CcSEcCtD
Doxorubicin—Myalgia—Metformin—polycystic ovary syndrome	0.000128	0.00785	CcSEcCtD
Doxorubicin—Chest pain—Metformin—polycystic ovary syndrome	0.000128	0.00785	CcSEcCtD
Doxorubicin—CYP1B1—uterus—polycystic ovary syndrome	0.000128	0.00287	CbGeAlD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000127	0.0078	CcSEcCtD
Doxorubicin—Discomfort—Metformin—polycystic ovary syndrome	0.000126	0.00776	CcSEcCtD
Doxorubicin—CYP1B1—pituitary gland—polycystic ovary syndrome	0.000125	0.00282	CbGeAlD
Doxorubicin—CYP1B1—adipose tissue—polycystic ovary syndrome	0.000125	0.00281	CbGeAlD
Doxorubicin—ABCC1—endometrium—polycystic ovary syndrome	0.000125	0.0028	CbGeAlD
Doxorubicin—ABCC3—endocrine gland—polycystic ovary syndrome	0.000124	0.00279	CbGeAlD
Doxorubicin—ABCC10—endocrine gland—polycystic ovary syndrome	0.000123	0.00278	CbGeAlD
Doxorubicin—Oedema—Metformin—polycystic ovary syndrome	0.000122	0.00753	CcSEcCtD
Doxorubicin—Infection—Metformin—polycystic ovary syndrome	0.000122	0.00748	CcSEcCtD
Doxorubicin—Shock—Metformin—polycystic ovary syndrome	0.00012	0.00741	CcSEcCtD
Doxorubicin—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00012	0.00738	CcSEcCtD
Doxorubicin—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00012	0.00737	CcSEcCtD
Doxorubicin—Skin disorder—Metformin—polycystic ovary syndrome	0.000119	0.00731	CcSEcCtD
Doxorubicin—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000118	0.00728	CcSEcCtD
Doxorubicin—Anorexia—Metformin—polycystic ovary syndrome	0.000117	0.00718	CcSEcCtD
Doxorubicin—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000116	0.0026	CbGeAlD
Doxorubicin—ABCC1—uterus—polycystic ovary syndrome	0.000115	0.00258	CbGeAlD
Doxorubicin—Hypotension—Metformin—polycystic ovary syndrome	0.000114	0.00704	CcSEcCtD
Doxorubicin—ABCC2—adrenal gland—polycystic ovary syndrome	0.000114	0.00257	CbGeAlD
Doxorubicin—ABCC1—pituitary gland—polycystic ovary syndrome	0.000113	0.00254	CbGeAlD
Doxorubicin—ABCC1—adipose tissue—polycystic ovary syndrome	0.000112	0.00253	CbGeAlD
Doxorubicin—CYP1B1—adrenal gland—polycystic ovary syndrome	0.000112	0.00252	CbGeAlD
Doxorubicin—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000112	0.00686	CcSEcCtD
Doxorubicin—Paraesthesia—Metformin—polycystic ovary syndrome	0.00011	0.00676	CcSEcCtD
Doxorubicin—Dyspnoea—Metformin—polycystic ovary syndrome	0.000109	0.00671	CcSEcCtD
Doxorubicin—Somnolence—Metformin—polycystic ovary syndrome	0.000109	0.00669	CcSEcCtD
Doxorubicin—Dyspepsia—Metformin—polycystic ovary syndrome	0.000108	0.00663	CcSEcCtD
Doxorubicin—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.000107	0.0024	CbGeAlD
Doxorubicin—Decreased appetite—Metformin—polycystic ovary syndrome	0.000106	0.00655	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000106	0.0065	CcSEcCtD
Doxorubicin—Fatigue—Metformin—polycystic ovary syndrome	0.000106	0.00649	CcSEcCtD
Doxorubicin—Constipation—Metformin—polycystic ovary syndrome	0.000105	0.00644	CcSEcCtD
Doxorubicin—CYP1B1—female gonad—polycystic ovary syndrome	0.000104	0.00235	CbGeAlD
Doxorubicin—ABCG2—endometrium—polycystic ovary syndrome	0.000103	0.00232	CbGeAlD
Doxorubicin—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000101	0.0062	CcSEcCtD
Doxorubicin—ABCC1—adrenal gland—polycystic ovary syndrome	0.000101	0.00227	CbGeAlD
Doxorubicin—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.0001	0.00616	CcSEcCtD
Doxorubicin—ABCC2—endocrine gland—polycystic ovary syndrome	9.92e-05	0.00223	CbGeAlD
Doxorubicin—Urticaria—Metformin—polycystic ovary syndrome	9.73e-05	0.00598	CcSEcCtD
Doxorubicin—CYP1B1—endocrine gland—polycystic ovary syndrome	9.71e-05	0.00219	CbGeAlD
Doxorubicin—Abdominal pain—Metformin—polycystic ovary syndrome	9.68e-05	0.00595	CcSEcCtD
Doxorubicin—ABCG2—uterus—polycystic ovary syndrome	9.51e-05	0.00214	CbGeAlD
Doxorubicin—ABCC1—female gonad—polycystic ovary syndrome	9.39e-05	0.00211	CbGeAlD
Doxorubicin—ABCC1—vagina—polycystic ovary syndrome	9.34e-05	0.0021	CbGeAlD
Doxorubicin—ABCG2—pituitary gland—polycystic ovary syndrome	9.33e-05	0.0021	CbGeAlD
Doxorubicin—ABCG2—adipose tissue—polycystic ovary syndrome	9.3e-05	0.00209	CbGeAlD
Doxorubicin—Asthenia—Metformin—polycystic ovary syndrome	8.78e-05	0.0054	CcSEcCtD
Doxorubicin—Pruritus—Metformin—polycystic ovary syndrome	8.66e-05	0.00533	CcSEcCtD
Doxorubicin—Diarrhoea—Metformin—polycystic ovary syndrome	8.38e-05	0.00515	CcSEcCtD
Doxorubicin—ABCG2—adrenal gland—polycystic ovary syndrome	8.34e-05	0.00188	CbGeAlD
Doxorubicin—Dizziness—Metformin—polycystic ovary syndrome	8.1e-05	0.00498	CcSEcCtD
Doxorubicin—Vomiting—Metformin—polycystic ovary syndrome	7.78e-05	0.00479	CcSEcCtD
Doxorubicin—ABCG2—female gonad—polycystic ovary syndrome	7.78e-05	0.00175	CbGeAlD
Doxorubicin—ABCG2—vagina—polycystic ovary syndrome	7.73e-05	0.00174	CbGeAlD
Doxorubicin—Rash—Metformin—polycystic ovary syndrome	7.72e-05	0.00475	CcSEcCtD
Doxorubicin—Dermatitis—Metformin—polycystic ovary syndrome	7.71e-05	0.00474	CcSEcCtD
Doxorubicin—CYP2B6—adrenal gland—polycystic ovary syndrome	7.69e-05	0.00173	CbGeAlD
Doxorubicin—Headache—Metformin—polycystic ovary syndrome	7.67e-05	0.00472	CcSEcCtD
Doxorubicin—Nausea—Metformin—polycystic ovary syndrome	7.27e-05	0.00447	CcSEcCtD
Doxorubicin—CYP2B6—vagina—polycystic ovary syndrome	7.13e-05	0.0016	CbGeAlD
Doxorubicin—ABCB1—embryo—polycystic ovary syndrome	6.95e-05	0.00156	CbGeAlD
Doxorubicin—CYP2B6—endocrine gland—polycystic ovary syndrome	6.67e-05	0.0015	CbGeAlD
Doxorubicin—ABCB1—adrenal cortex—polycystic ovary syndrome	5.7e-05	0.00128	CbGeAlD
Doxorubicin—CYP2D6—female gonad—polycystic ovary syndrome	5.33e-05	0.0012	CbGeAlD
Doxorubicin—ABCB1—endometrium—polycystic ovary syndrome	5.09e-05	0.00114	CbGeAlD
Doxorubicin—CYP3A4—endocrine gland—polycystic ovary syndrome	5.04e-05	0.00113	CbGeAlD
Doxorubicin—CYP2D6—endocrine gland—polycystic ovary syndrome	4.96e-05	0.00112	CbGeAlD
Doxorubicin—ABCB1—uterus—polycystic ovary syndrome	4.69e-05	0.00106	CbGeAlD
Doxorubicin—ABCB1—pituitary gland—polycystic ovary syndrome	4.6e-05	0.00104	CbGeAlD
Doxorubicin—ABCB1—adipose tissue—polycystic ovary syndrome	4.58e-05	0.00103	CbGeAlD
Doxorubicin—ABCB1—adrenal gland—polycystic ovary syndrome	4.11e-05	0.000926	CbGeAlD
Doxorubicin—ABCB1—female gonad—polycystic ovary syndrome	3.83e-05	0.000863	CbGeAlD
Doxorubicin—ABCB1—vagina—polycystic ovary syndrome	3.81e-05	0.000858	CbGeAlD
Doxorubicin—ABCB1—endocrine gland—polycystic ovary syndrome	3.57e-05	0.000803	CbGeAlD
Doxorubicin—NOS3—Metabolism—NCOR1—polycystic ovary syndrome	2.9e-06	4.42e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PRL—polycystic ovary syndrome	2.89e-06	4.41e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—INS—polycystic ovary syndrome	2.88e-06	4.39e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—YAP1—polycystic ovary syndrome	2.88e-06	4.39e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SERPINE1—polycystic ovary syndrome	2.88e-06	4.39e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	2.87e-06	4.38e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.87e-06	4.38e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NAMPT—polycystic ovary syndrome	2.86e-06	4.36e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.84e-06	4.34e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	2.83e-06	4.32e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP11A1—polycystic ovary syndrome	2.82e-06	4.31e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—SLC2A4—polycystic ovary syndrome	2.82e-06	4.3e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—MTHFR—polycystic ovary syndrome	2.82e-06	4.3e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRG1—polycystic ovary syndrome	2.81e-06	4.3e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—SULT2A1—polycystic ovary syndrome	2.8e-06	4.28e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.8e-06	4.28e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	2.79e-06	4.26e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	2.79e-06	4.26e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT2—polycystic ovary syndrome	2.78e-06	4.25e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CYP19A1—polycystic ovary syndrome	2.76e-06	4.22e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NAMPT—polycystic ovary syndrome	2.76e-06	4.22e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.75e-06	4.2e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CYP1A1—polycystic ovary syndrome	2.75e-06	4.19e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.74e-06	4.19e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP11A1—polycystic ovary syndrome	2.73e-06	4.17e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—RRM2—polycystic ovary syndrome	2.71e-06	4.15e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HMMR—polycystic ovary syndrome	2.71e-06	4.14e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.71e-06	4.14e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TCF7L2—polycystic ovary syndrome	2.68e-06	4.1e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	2.68e-06	4.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKR1C3—polycystic ovary syndrome	2.66e-06	4.07e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP19A1—polycystic ovary syndrome	2.65e-06	4.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SERPINE1—polycystic ovary syndrome	2.64e-06	4.04e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.64e-06	4.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SLC2A4—polycystic ovary syndrome	2.64e-06	4.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP17A1—polycystic ovary syndrome	2.62e-06	4.01e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—YAP1—polycystic ovary syndrome	2.62e-06	4e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HSD3B1—polycystic ovary syndrome	2.59e-06	3.95e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKR1C3—polycystic ovary syndrome	2.58e-06	3.94e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—MTHFR—polycystic ovary syndrome	2.56e-06	3.91e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PPARG—polycystic ovary syndrome	2.55e-06	3.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—GNAS—polycystic ovary syndrome	2.54e-06	3.88e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IRS1—polycystic ovary syndrome	2.54e-06	3.88e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP17A1—polycystic ovary syndrome	2.54e-06	3.87e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	2.52e-06	3.85e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PRL—polycystic ovary syndrome	2.51e-06	3.84e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NAMPT—polycystic ovary syndrome	2.51e-06	3.84e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—POMC—polycystic ovary syndrome	2.51e-06	3.84e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—INS—polycystic ovary syndrome	2.5e-06	3.81e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP11A1—polycystic ovary syndrome	2.48e-06	3.79e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	2.48e-06	3.79e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GNAS—polycystic ovary syndrome	2.47e-06	3.77e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PPARG—polycystic ovary syndrome	2.46e-06	3.75e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	2.45e-06	3.74e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—INS—polycystic ovary syndrome	2.43e-06	3.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—POMC—polycystic ovary syndrome	2.42e-06	3.7e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.42e-06	3.7e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IRS2—polycystic ovary syndrome	2.41e-06	3.68e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—INS—polycystic ovary syndrome	2.41e-06	3.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRG1—polycystic ovary syndrome	2.38e-06	3.63e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GNAS—polycystic ovary syndrome	2.36e-06	3.61e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—LEP—polycystic ovary syndrome	2.36e-06	3.6e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—LHB—polycystic ovary syndrome	2.36e-06	3.6e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	2.35e-06	3.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT2—polycystic ovary syndrome	2.35e-06	3.59e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—NCOR1—polycystic ovary syndrome	2.35e-06	3.59e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKR1C3—polycystic ovary syndrome	2.34e-06	3.58e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	2.34e-06	3.57e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP17A1—polycystic ovary syndrome	2.31e-06	3.52e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	2.31e-06	3.52e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	2.31e-06	3.52e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HSD3B2—polycystic ovary syndrome	2.31e-06	3.52e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.3e-06	3.51e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PPARG—polycystic ovary syndrome	2.28e-06	3.49e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—TH—polycystic ovary syndrome	2.27e-06	3.47e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—POMC—polycystic ovary syndrome	2.25e-06	3.44e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—NCOR1—polycystic ovary syndrome	2.25e-06	3.44e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—STAR—polycystic ovary syndrome	2.24e-06	3.43e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	2.24e-06	3.42e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—INS—polycystic ovary syndrome	2.24e-06	3.42e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SERPINE1—polycystic ovary syndrome	2.23e-06	3.41e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKR1C1—polycystic ovary syndrome	2.23e-06	3.41e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CYP1A1—polycystic ovary syndrome	2.23e-06	3.4e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	2.22e-06	3.38e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—SLC2A4—polycystic ovary syndrome	2.21e-06	3.37e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—TH—polycystic ovary syndrome	2.2e-06	3.35e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	2.14e-06	3.28e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	2.14e-06	3.27e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP1A1—polycystic ovary syndrome	2.14e-06	3.26e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—SLC2A4—polycystic ovary syndrome	2.14e-06	3.26e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	2.11e-06	3.23e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NCOR1—polycystic ovary syndrome	2.11e-06	3.22e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IRS1—polycystic ovary syndrome	2.1e-06	3.21e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—MTHFR—polycystic ovary syndrome	2.08e-06	3.17e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PPARG—polycystic ovary syndrome	2.08e-06	3.17e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP19A1—polycystic ovary syndrome	2.08e-06	3.17e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRG1—polycystic ovary syndrome	2.07e-06	3.16e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SULT2A1—polycystic ovary syndrome	2.05e-06	3.14e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—POMC—polycystic ovary syndrome	2.05e-06	3.13e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IRS2—polycystic ovary syndrome	2.04e-06	3.11e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—INS—polycystic ovary syndrome	2.04e-06	3.11e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—POMC—polycystic ovary syndrome	2.03e-06	3.09e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—INS—polycystic ovary syndrome	2.01e-06	3.08e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP19A1—polycystic ovary syndrome	2.01e-06	3.07e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	2.01e-06	3.06e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	2e-06	3.05e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—TH—polycystic ovary syndrome	2e-06	3.05e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—LEP—polycystic ovary syndrome	1.99e-06	3.04e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—MTHFR—polycystic ovary syndrome	1.99e-06	3.04e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—RRM2—polycystic ovary syndrome	1.99e-06	3.04e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.95e-06	2.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.95e-06	2.97e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—SLC2A4—polycystic ovary syndrome	1.94e-06	2.97e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—YAP1—polycystic ovary syndrome	1.92e-06	2.93e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	1.91e-06	2.91e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	1.88e-06	2.88e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.88e-06	2.87e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MTHFR—polycystic ovary syndrome	1.86e-06	2.84e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GNAS—polycystic ovary syndrome	1.85e-06	2.83e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.85e-06	2.83e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NAMPT—polycystic ovary syndrome	1.84e-06	2.81e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP19A1—polycystic ovary syndrome	1.83e-06	2.79e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	1.82e-06	2.79e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	1.82e-06	2.79e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP11A1—polycystic ovary syndrome	1.82e-06	2.78e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—IL6—polycystic ovary syndrome	1.81e-06	2.77e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.8e-06	2.75e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GNAS—polycystic ovary syndrome	1.79e-06	2.74e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.78e-06	2.71e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IRS2—polycystic ovary syndrome	1.77e-06	2.71e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NCOR1—polycystic ovary syndrome	1.77e-06	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—LHB—polycystic ovary syndrome	1.74e-06	2.66e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKR1C3—polycystic ovary syndrome	1.72e-06	2.62e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—POMC—polycystic ovary syndrome	1.71e-06	2.61e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NCOR1—polycystic ovary syndrome	1.71e-06	2.61e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—INS—polycystic ovary syndrome	1.7e-06	2.6e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	1.7e-06	2.6e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP17A1—polycystic ovary syndrome	1.69e-06	2.58e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PPARG—polycystic ovary syndrome	1.68e-06	2.57e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP1A1—polycystic ovary syndrome	1.67e-06	2.56e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—POMC—polycystic ovary syndrome	1.66e-06	2.54e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—INS—polycystic ovary syndrome	1.65e-06	2.52e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.65e-06	2.51e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	1.65e-06	2.51e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.65e-06	2.51e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.64e-06	2.5e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	1.63e-06	2.49e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP1A1—polycystic ovary syndrome	1.62e-06	2.47e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PPARG—polycystic ovary syndrome	1.61e-06	2.47e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.6e-06	2.45e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—POMC—polycystic ovary syndrome	1.59e-06	2.43e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—polycystic ovary syndrome	1.59e-06	2.43e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—INS—polycystic ovary syndrome	1.58e-06	2.42e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.56e-06	2.39e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—MTHFR—polycystic ovary syndrome	1.56e-06	2.38e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	1.55e-06	2.37e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.55e-06	2.37e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IRS1—polycystic ovary syndrome	1.55e-06	2.36e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.53e-06	2.33e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	1.52e-06	2.31e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—MTHFR—polycystic ovary syndrome	1.51e-06	2.3e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—INS—polycystic ovary syndrome	1.48e-06	2.26e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	1.47e-06	2.25e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	1.47e-06	2.24e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TH—polycystic ovary syndrome	1.46e-06	2.24e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1.45e-06	2.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT2—polycystic ovary syndrome	1.43e-06	2.19e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.43e-06	2.18e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SLC2A4—polycystic ovary syndrome	1.42e-06	2.17e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	1.41e-06	2.16e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.38e-06	2.11e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.38e-06	2.11e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	1.37e-06	2.1e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—polycystic ovary syndrome	1.37e-06	2.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SERPINE1—polycystic ovary syndrome	1.36e-06	2.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	1.36e-06	2.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	1.34e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	1.34e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.33e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.28e-06	1.96e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.27e-06	1.94e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	1.27e-06	1.94e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—polycystic ovary syndrome	1.26e-06	1.93e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.26e-06	1.93e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—polycystic ovary syndrome	1.26e-06	1.92e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	1.25e-06	1.91e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—POMC—polycystic ovary syndrome	1.25e-06	1.91e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—INS—polycystic ovary syndrome	1.24e-06	1.89e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.23e-06	1.88e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—polycystic ovary syndrome	1.22e-06	1.87e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—POMC—polycystic ovary syndrome	1.21e-06	1.84e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—INS—polycystic ovary syndrome	1.2e-06	1.83e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	1.2e-06	1.83e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.19e-06	1.82e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.18e-06	1.8e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.18e-06	1.79e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	1.14e-06	1.74e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	1.11e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—POMC—polycystic ovary syndrome	1.1e-06	1.68e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—INS—polycystic ovary syndrome	1.09e-06	1.67e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TH—polycystic ovary syndrome	1.08e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	1.08e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.08e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.07e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—polycystic ovary syndrome	1.06e-06	1.62e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	1.05e-06	1.6e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.05e-06	1.6e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.02e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.01e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	1.01e-06	1.54e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	9.9e-07	1.51e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	9.88e-07	1.51e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	9.34e-07	1.43e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	9.31e-07	1.42e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	9.04e-07	1.38e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	8.81e-07	1.35e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—polycystic ovary syndrome	8.8e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	8.72e-07	1.33e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	8.4e-07	1.28e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	8.37e-07	1.28e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	8.31e-07	1.27e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	8.27e-07	1.26e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	8.16e-07	1.25e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	8.05e-07	1.23e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—INS—polycystic ovary syndrome	8e-07	1.22e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	7.96e-07	1.22e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	7.91e-07	1.21e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	7.81e-07	1.19e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	7.69e-07	1.17e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	7.5e-07	1.15e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—polycystic ovary syndrome	7.44e-07	1.14e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	7.42e-07	1.13e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	6.99e-07	1.07e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TH—polycystic ovary syndrome	6.65e-07	1.02e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—polycystic ovary syndrome	6.47e-07	9.89e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	6.47e-07	9.88e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	6.08e-07	9.29e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	6.02e-07	9.19e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—POMC—polycystic ovary syndrome	5.94e-07	9.06e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—INS—polycystic ovary syndrome	5.9e-07	9.01e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	5.67e-07	8.66e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	5.59e-07	8.54e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—INS—polycystic ovary syndrome	5.56e-07	8.49e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	5.43e-07	8.29e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	5.17e-07	7.9e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	4.9e-07	7.49e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	4.57e-07	6.98e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	3.71e-07	5.66e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	3.66e-07	5.58e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—INS—polycystic ovary syndrome	3.64e-07	5.55e-06	CbGpPWpGaD
